Tyrosinase promoter and enhancer system (TETP)

The Melanoma-cell–restricted transcriptional machinery via the TETP system is a specialized gene expression platform designed for targeted melanoma therapy (Kim et al., 2002). It consists of the Tyrosinase Enhancer (TE) and Tyrosinase Promoter (TP) sequences, which are naturally regulated by the Microphthalmia-associated transcription factor (MITF) found predominantly in melanocytes and melanoma cells (Levy et al., 2006). By incorporating this system into viral or non-viral vectors, researchers can drive the selective expression of therapeutic agents, such as suicide genes like Diphtheria toxin A (DTA) or immunostimulatory cytokines, specifically within the tumor microenvironment (Siders et al., 1998). While highly specific, the primary challenge remains the potential for toxicity in healthy melanocytes, which can lead to autoimmune-like conditions such as vitiligo. Additionally, the potential for 'leaky' expression in non-melanoma tissues and the efficiency of delivery vectors are significant therapeutic hurdles. This system represents a form of 'transcriptional targeting' rather than a traditional molecular target like a receptor or enzyme, making it a tool for precision oncology rather than a target for small molecule inhibition.

Other names

Tyrosinase Enhancer/Tyrosinase Promoter systemTE/TP systemMelanoma-specific transcriptional machineryTyrosinase-driven expression system

Utilizes the melanocyte-specific activity of the tyrosinase promoter and enhancer to drive the expression of therapeutic genes (e.g., toxins or cytokines) exclusively within melanoma cells by recruiting endogenous transcription factors like MITF.